Letter by Barlis et al Regarding Article, “Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry

Abstract

To the Editor: The role of drug-eluting stents within the field of interventional cardiology has recently come under close scrutiny in the wake of increasing concerns about late stent thrombosis and doubts on the overall cost-effectiveness of these devices. The prevailing view among experts, however, is that this technology retains an important role, particularly in patients at high risk of restenosis such as those with diabetes mellitus, as suggested by randomized trials.1 It was thus with great interest that we read the article by Ortolani et al,2 which presents the results …